
|Articles|June 17, 2014 (Updated: April 18, 2020)
- Precision Diagnostics
- Volume 1
- Issue 1
Comparing Urine and Plasma Cell-Free DNA <em>BRAFV600E</em> Testing to Tissue Biopsy Mutation Testing
Author(s)Eli L. Diamond, MD
Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses an analysis that looked at urine and plasma cell-free DNA BRAFV600E testing compared with tissue biopsy mutation testing.
Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses an analysis that looked at urine and plasma cell-free DNABRAFV600Etesting compared with tissue biopsy mutation testing. This analysis was presented at the 2014 ASCO Annual Meeting.
Read about DNA in urine as a liquid biopsy for cancers and rare diseases > >
Articles in this issue
over 11 years ago
The Importance of Urine Tests for Mutation Detectionover 11 years ago
Tumor Mutational Analysis Using Urinary Cell-Free DNARelated Content
Advertisement


Safety and Antitumor Activity Revealed for T-Cell Engager XmAb819 in RCC
Published: | Updated:

Sarcomatoid Features May Be a Biomarker in Chromophobe RCC
Published: | Updated:

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
Published: | Updated:




























